Zev A. Binder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zev A. Binder has a total of 323 co-authors. Here are the top co-authors by number of shared publications:
- Donald M. O'ROurke
Glioblastoma Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, USA
38 shared publications - Stephen J. Bagley
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
17 shared publications - Arati Suvas Desai
Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
14 shared publications - Camilla Macia
Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
14 shared publications - Dominique Ballinger
Department of Medicine Division of Haematology‐Oncology, University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA
14 shared publications - Erica L. Carpenter
Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
14 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Topical Resiquimod Elicits Systemic Protection and Improves Anti–PD-1 Therapy in Melanoma via Priming of CD8+ T Cells
Supplementary Figure 5: Granzyme B and Ki-67 expression in CD8+ T cells in the MPDOs.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Topical Resiquimod Elicits Systemic Protection and Improves Anti–PD-1 Therapy in Melanoma via Priming of CD8+ T Cells
Supplementary Figure 5: Granzyme B and Ki-67 expression in CD8+ T cells in the MPDOs.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Topical Resiquimod Elicits Systemic Protection and Improves Anti–PD-1 Therapy in Melanoma via Priming of CD8+ T Cells
Supplementary Figure 3. Mouse body weight during treatment.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Topical Resiquimod Elicits Systemic Protection and Improves Anti–PD-1 Therapy in Melanoma via Priming of CD8+ T Cells
Supplementary Figure 3. Mouse body weight during treatment.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Data from Topical Resiquimod Elicits Systemic Protection and Improves Anti–PD-1 Therapy in Melanoma via Priming of CD8+ T Cells
The Toll-like receptor (TLR) 7/8 agonist resiquimod shows promise for treating cutaneous T-cell lymphoma and actinic keratosis, yet its mechanism of action remains unclear. We demonstrated that topical resiquimod significantly inhibited melanoma growth across various genetic and syngeneic mouse models, prolonged survival, and reduced lymph node metastasis in vivo. Resiquimod suppressed B16 melanoma growth, with an effect superior to that of imiquimod. The therapeutic effect was CD8+ T cell–dependent, as evidenced by the loss of efficacy upon CD8+ T-cell depletion or in Rag2−/− mice. Resiquimod increased intratumoral CD45+ inflammatory cells, particularly antigen-experienced PD-1+CD62L−CD8+ effector T cells, and enhanced their Ki-67 and granzyme B expression. Resiquimod significantly expanded Pmel- and Trp2-specific CD8+ T cells in the presence of dendritic cells (DC). Topical treatment of melanoma-bearing mice induced systemic protection in rechallenge experiments. In addition, combining topical resiquimod with anti–PD-1 antibodies led to superior inhibition of tumor growth and metastasis across multiple melanoma models. Proteomic analysis revealed increased granzyme B and CD26 and decreased phosphorylated FOXO3a after treatment. In patient-derived organoids and melanoma slice cultures, resiquimod induced significant tumor killing and CD8+ T-cell activation, further augmented by PD-1 antibodies. Our findings support the conclusion that resiquimod promotes CD8+ T-cell priming via DCs and enhances the therapeutic efficacy of anti–PD-1 checkpoint blockade in melanoma.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Topical Resiquimod Elicits Systemic Protection and Improves Anti–PD-1 Therapy in Melanoma via Priming of CD8+ T Cells
The Toll-like receptor (TLR) 7/8 agonist resiquimod shows promise for treating cutaneous T-cell lymphoma and actinic keratosis, yet its mechanism of action remains unclear. We demonstrated that topical resiquimod significantly inhibited melanoma growth across various genetic and syngeneic mouse models, prolonged survival, and reduced lymph node metastasis in vivo. Resiquimod suppressed B16 melanoma growth, with an effect superior to that of imiquimod. The therapeutic effect was CD8+ T cell–dependent, as evidenced by the loss of efficacy upon CD8+ T-cell depletion or in Rag2−/− mice. Resiquimod increased intratumoral CD45+ inflammatory cells, particularly antigen-experienced PD-1+CD62L−CD8+ effector T cells, and enhanced their Ki-67 and granzyme B expression. Resiquimod significantly expanded Pmel- and Trp2-specific CD8+ T cells in the presence of dendritic cells (DC). Topical treatment of melanoma-bearing mice induced systemic protection in rechallenge experiments. In addition, combining topical resiquimod with anti–PD-1 antibodies led to superior inhibition of tumor growth and metastasis across multiple melanoma models. Proteomic analysis revealed increased granzyme B and CD26 and decreased phosphorylated FOXO3a after treatment. In patient-derived organoids and melanoma slice cultures, resiquimod induced significant tumor killing and CD8+ T-cell activation, further augmented by PD-1 antibodies. Our findings support the conclusion that resiquimod promotes CD8+ T-cell priming via DCs and enhances the therapeutic efficacy of anti–PD-1 checkpoint blockade in melanoma.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Topical Resiquimod Elicits Systemic Protection and Improves Anti–PD-1 Therapy in Melanoma via Priming of CD8+ T Cells
Supplementary Figure 4: Effects of resiquimod on CD45-and CD45+ cell fractions in MPDOs.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Topical Resiquimod Elicits Systemic Protection and Improves Anti–PD-1 Therapy in Melanoma via Priming of CD8+ T Cells
Supplementary Figure 4: Effects of resiquimod on CD45-and CD45+ cell fractions in MPDOs.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Topical Resiquimod Elicits Systemic Protection and Improves Anti–PD-1 Therapy in Melanoma via Priming of CD8+ T Cells
Supplementary Figure 1. Representative mouse genotypes by PCR. Different mouse genotypes were illustrated.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Topical Resiquimod Elicits Systemic Protection and Improves Anti–PD-1 Therapy in Melanoma via Priming of CD8+ T Cells
Supplementary Figure 1. Representative mouse genotypes by PCR. Different mouse genotypes were illustrated.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Topical Resiquimod Elicits Systemic Protection and Improves Anti–PD-1 Therapy in Melanoma via Priming of CD8+ T Cells
Supplementary Figure 2. Cytokine expression in Tyr::creER, Brafca, Ptenlox/lox mouse tumors after resiquimod treatment.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Topical Resiquimod Elicits Systemic Protection and Improves Anti–PD-1 Therapy in Melanoma via Priming of CD8+ T Cells
Supplementary Figure 2. Cytokine expression in Tyr::creER, Brafca, Ptenlox/lox mouse tumors after resiquimod treatment.
- Open Access
The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM
- 11 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (9) , 1496-1509
Topical resiquimod elicits systemic protection and improves anti-PD1 therapy in melanoma via priming of CD8+ T cells
The Toll-like receptor (TLR) 7/8 agonist resiquimod shows promise for treating cutaneous T cell lymphoma and actinic keratosis, yet its mechanism of action remains unclear. We demonstrated that topical resiquimod significantly inhibited melanoma growth across various genetic and syngeneic mouse models, prolonged survival, and reduced lymph node metastasis in vivo. Resiquimod suppressed B16 melanoma growth, with an effect superior to that of imiquimod. The therapeutic effect was CD8+ T cell-dependent, as evidenced by the loss of efficacy upon CD8+ T cell depletion or in Rag2-/- mice. Resiquimod increased intratumoral CD45+ inflammatory cells, particularly antigen-experienced PD1+CD62L-CD8+ effector T cells, and enhanced their Ki-67 and Granzyme B expression. Resiquimod significantly expanded Pmel- and Trp2-specific CD8+ T cells in the presence of dendritic cells. Topical treatment of melanoma-bearing mice induced systemic protection in rechallenge experiments. In addition, combining topical resiquimod with anti-PD-1 antibodies led to superior inhibition of tumor growth and metastasis across multiple melanoma models. Proteomic analysis revealed increased Granzyme B and CD26, and decreased phosphorylated FOXO3a, post-treatment. In patient-derived organoids and melanoma slice cultures, resiquimod induced significant tumor killing and CD8+ T cell activation, further augmented by PD-1 antibodies. Our findings support the conclusion that resiquimod promotes CD8+ T-cell priming via dendritic cells and enhances the therapeutic efficacy of anti-PD-1 checkpoint blockade in melanoma.
- 11 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (9) , 1496-1509
Topical resiquimod elicits systemic protection and improves anti-PD1 therapy in melanoma via priming of CD8+ T cells
The Toll-like receptor (TLR) 7/8 agonist resiquimod shows promise for treating cutaneous T cell lymphoma and actinic keratosis, yet its mechanism of action remains unclear. We demonstrated that topical resiquimod significantly inhibited melanoma growth across various genetic and syngeneic mouse models, prolonged survival, and reduced lymph node metastasis in vivo. Resiquimod suppressed B16 melanoma growth, with an effect superior to that of imiquimod. The therapeutic effect was CD8+ T cell-dependent, as evidenced by the loss of efficacy upon CD8+ T cell depletion or in Rag2-/- mice. Resiquimod increased intratumoral CD45+ inflammatory cells, particularly antigen-experienced PD1+CD62L-CD8+ effector T cells, and enhanced their Ki-67 and Granzyme B expression. Resiquimod significantly expanded Pmel- and Trp2-specific CD8+ T cells in the presence of dendritic cells. Topical treatment of melanoma-bearing mice induced systemic protection in rechallenge experiments. In addition, combining topical resiquimod with anti-PD-1 antibodies led to superior inhibition of tumor growth and metastasis across multiple melanoma models. Proteomic analysis revealed increased Granzyme B and CD26, and decreased phosphorylated FOXO3a, post-treatment. In patient-derived organoids and melanoma slice cultures, resiquimod induced significant tumor killing and CD8+ T cell activation, further augmented by PD-1 antibodies. Our findings support the conclusion that resiquimod promotes CD8+ T-cell priming via dendritic cells and enhances the therapeutic efficacy of anti-PD-1 checkpoint blockade in melanoma.
- 1 December 2025
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 23 (2) , 137-150
The development of CAR T cells for patients with CNS malignancies
Chimeric antigen receptor (CAR) T cells have become standard-of-care therapies for patients with certain relapsed and/or refractory haematological malignancies over the past decade. However, this approach remains largely ineffective in patients with solid tumours, in part owing to limited CAR T cell persistence, the immunosuppressive tumour microenvironment of many solid tumours and limited trafficking of CAR T cells into tumours. Central nervous system (CNS) tumours, many of which are associated with a poor prognosis and require new treatment approaches, present additional challenges such as the presence of the blood–brain barrier as well as concerns over treatment-related neurotoxicities. Despite these difficulties, clinical trials involving both adult and paediatric patients with primary CNS tumours have provided signals of efficacy. In this Review, we discuss completed, ongoing and anticipated trials testing CAR T cells in patients with CNS tumours. We also highlight the most promising preclinical developments that might lead to novel clinical approaches in this area.
- 1 December 2025
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 23 (2) , 137-150
The development of CAR T cells for patients with CNS malignancies
Chimeric antigen receptor (CAR) T cells have become standard-of-care therapies for patients with certain relapsed and/or refractory haematological malignancies over the past decade. However, this approach remains largely ineffective in patients with solid tumours, in part owing to limited CAR T cell persistence, the immunosuppressive tumour microenvironment of many solid tumours and limited trafficking of CAR T cells into tumours. Central nervous system (CNS) tumours, many of which are associated with a poor prognosis and require new treatment approaches, present additional challenges such as the presence of the blood–brain barrier as well as concerns over treatment-related neurotoxicities. Despite these difficulties, clinical trials involving both adult and paediatric patients with primary CNS tumours have provided signals of efficacy. In this Review, we discuss completed, ongoing and anticipated trials testing CAR T cells in patients with CNS tumours. We also highlight the most promising preclinical developments that might lead to novel clinical approaches in this area.
- Open Access
- 17 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (42) , eadx7687
Hydralazine inhibits cysteamine dioxygenase to treat preeclampsia and senesce glioblastoma
Hydralazine (HYZ), a treatment for preeclampsia and hypertensive crisis, is listed by the World Health Organization as an essential medicine. Its mode of action has remained unknown through its seven decades of clinical use. Here, we identify 2-aminoethanethiol dioxygenase (ADO), a key mediator of targeted protein degradation, as a selective HYZ target. The drug chelates ADO’s metallocofactor and can alkylate one of its ligands. The resultant inactivation stabilizes regulators of G protein signaling (RGS4 and RGS5) that ADO normally marks for proteolysis, explaining the drug’s vasodilatory activity and comporting with observations of diminished RGS levels in both clinical preeclampsia and a mouse model thereof. Its inhibition of ADO suggested use of HYZ against glioblastoma (GBM); indeed, a single dose robustly senesces cultured GBM cells. By establishing ADO as a nexus for GBM and preeclampsia and connecting it to HYZ, the results create opportunities for directed tailoring of the old drug for new therapies.
- 17 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (42) , eadx7687
Open AccessHydralazine inhibits cysteamine dioxygenase to treat preeclampsia and senesce glioblastoma
Hydralazine (HYZ), a treatment for preeclampsia and hypertensive crisis, is listed by the World Health Organization as an essential medicine. Its mode of action has remained unknown through its seven decades of clinical use. Here, we identify 2-aminoethanethiol dioxygenase (ADO), a key mediator of targeted protein degradation, as a selective HYZ target. The drug chelates ADO’s metallocofactor and can alkylate one of its ligands. The resultant inactivation stabilizes regulators of G protein signaling (RGS4 and RGS5) that ADO normally marks for proteolysis, explaining the drug’s vasodilatory activity and comporting with observations of diminished RGS levels in both clinical preeclampsia and a mouse model thereof. Its inhibition of ADO suggested use of HYZ against glioblastoma (GBM); indeed, a single dose robustly senesces cultured GBM cells. By establishing ADO as a nexus for GBM and preeclampsia and connecting it to HYZ, the results create opportunities for directed tailoring of the old drug for new therapies.